BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35691019)

  • 1. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
    Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
    Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in
    Wang R; Sheps JA; Liu L; Han J; Chen PSK; Lamontagne J; Wilson PD; Welch I; Borchers CH; Ling V
    J Lipid Res; 2019 Jan; 60(1):85-97. PubMed ID: 30416103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic preconditioning protects BSEP/ABCB11
    Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
    J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
    Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
    J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
    Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
    Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.
    Glaser F; John C; Engel B; Höh B; Weidemann S; Dieckhoff J; Stein S; Becker N; Casar C; Schuran FA; Wieschendorf B; Preti M; Jessen F; Franke A; Carambia A; Lohse AW; Ittrich H; Herkel J; Heeren J; Schramm C; Schwinge D
    J Hepatol; 2019 Oct; 71(4):783-792. PubMed ID: 31207266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/β-Catenin Signaling Plays a Protective Role in the Mdr2 Knockout Murine Model of Cholestatic Liver Disease.
    Pradhan-Sundd T; Kosar K; Saggi H; Zhang R; Vats R; Cornuet P; Green S; Singh S; Zeng G; Sundd P; Nejak-Bowen K
    Hepatology; 2020 May; 71(5):1732-1749. PubMed ID: 31489648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colesevelam attenuates cholestatic liver and bile duct injury in
    Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
    Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
    Li X; Liu R; Yang J; Sun L; Zhang L; Jiang Z; Puri P; Gurley EC; Lai G; Tang Y; Huang Z; Pandak WM; Hylemon PB; Zhou H
    Hepatology; 2017 Sep; 66(3):869-884. PubMed ID: 28271527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
    Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
    Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
    J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protective role of hydrophilic tetrahydroxylated bile acids (THBA).
    Sheps JA; Wang R; Wang J; Ling V
    Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Jul; 1866(7):158925. PubMed ID: 33713832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    Cai SY; Yu D; Soroka CJ; Wang J; Boyer JL
    J Hepatol; 2021 Mar; 74(3):550-559. PubMed ID: 33039404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockout of the Tachykinin Receptor 1 in the Mdr2
    Ceci L; Francis H; Zhou T; Giang T; Yang Z; Meng F; Wu N; Kennedy L; Kyritsi K; Meadows V; Wu C; Liangpunsakul S; Franchitto A; Sybenga A; Ekser B; Mancinelli R; Onori P; Gaudio E; Glaser S; Alpini G
    Am J Pathol; 2020 Nov; 190(11):2251-2266. PubMed ID: 32712019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
    Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
    Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
    Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
    JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
    Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
    Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis.
    Liu R; Li X; Zhu W; Wang Y; Zhao D; Wang X; Gurley EC; Liang G; Chen W; Lai G; Pandak WM; Robert Lippman H; Bajaj JS; Hylemon PB; Zhou H
    Hepatology; 2019 Oct; 70(4):1317-1335. PubMed ID: 30985008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
    Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
    Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Remetic J; Ghallab A; Hobloss Z; Brackhagen L; Hassan R; Myllys M; Radun R; Mlitz V; Zhu C; Baumgartner M; Schrottmaier WC; Mussbacher M; Timelthaler G; Scharnagl H; Stojakovic T; Assinger A; Fuchs CD; Hengstler JG; Trauner M
    Hepatology; 2022 May; 75(5):1095-1109. PubMed ID: 34927748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.